Anesth Analg 2008; 106:725-731
© 2008 International Anesthesia Research Society
doi: 10.1213/ane.0b013e318163fb26
CARDIOVASCULAR ANESTHESIOLOGY
Fibrinogen in Craniosynostosis Surgery
Thorsten Haas, MD*,
Dietmar Fries, MD ,
Corinna Velik-Salchner, MD*,
Elgar Oswald, MD*, and
Petra Innerhofer, MD*
From the Departments of *Anaesthesiology and Critical Care Medicine, and General and Surgical Critical Care Medicine, Innsbruck Medical University, Innsbruck, Austria.
Address correspondence and reprint requests to Thorsten Haas, MD, Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria. Address e-mail to thorsten.haas{at}i-med.ac.at.
Abstract
BACKGROUND: During craniosynostosis repair, massive blood loss, consumption and dilution of clotting factors often result in coagulopathy, for which cryoprecipitate, fresh frozen plasma (FFP), and platelets are recommended for treatment. However, cryoprecipitate is not available in most European countries, and the efficacy of FFP in correcting fibrinogen deficiency is limited. We report our experience with human fibrinogen concentrate (Hemocomplettan®) used to improve impaired fibrinogen polymerization in children.
METHODS: Results of routine coagulation tests, thrombelastometry (ROTEM®), transfusion requirements, administration of fibrinogen concentrate, and data on the postoperative course of nine consecutive children undergoing major craniofacial surgery were retrospectively collected from anesthesia protocols, medical charts, laboratory and ROTEM® databases.
RESULTS: The nine children aged 12 (8, 22) mo (median [25th, 75th percentile]), weighing 9.5 (9, 10) kg had a calculated blood loss of 80 (49, 92)% of calculated blood volume during the surgery lasting 6.4 (4.5, 7.2) h. Impaired fibrinogen polymerization detected by ROTEM® was the main problem underlying dilutional coagulopathy. In all cases, sufficient hemostasis was achieved without adverse effects by administering (if necessary), repeated doses of fibrinogen concentrates (each single dose 30 mg/kg) without FFP or platelet transfusions. All children were successfully weaned from mechanical ventilation within a few hours and were able to be discharged early from the Intensive Care Unit.
CONCLUSIONS: Administration of fibrinogen concentrate effectively improves fibrinogen polymerization and total clot strength, which were the main underlying problems of dilutional coagulopathy in children undergoing craniosynostosis surgery.
This article has been cited by other articles:

|
 |

|
 |
 
C. Jambor, V. Reul, T. W. Schnider, P. Degiacomi, H. Metzner, and W. C. Korte
In Vitro Inhibition of Factor XIII Retards Clot Formation, Reduces Clot Firmness, and Increases Fibrinolytic Effects in Whole Blood
Anesth. Analg.,
October 1, 2009;
109(4):
1023 - 1028.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Rahe-Meyer, C. Solomon, M. Winterhalter, S. Piepenbrock, K. Tanaka, A. Haverich, and M. Pichlmaier
Thromboelastometry-guided administration of fibrinogen concentrate for the treatment of excessive intraoperative bleeding in thoracoabdominal aortic aneurysm surgery
J. Thorac. Cardiovasc. Surg.,
September 1, 2009;
138(3):
694 - 702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Maquoi, V. Bonhomme, J. D. Born, M.-F. Dresse, E. Ronge-Collard, J.-M. Minon, and P. Hans
Perioperative Management of a Child with von Willebrand Disease Undergoing Surgical Repair of Craniosynostosis: Looking at Unusual Targets
Anesth. Analg.,
September 1, 2009;
109(3):
720 - 724.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Rahe-Meyer, M. Pichlmaier, A. Haverich, C. Solomon, M. Winterhalter, S. Piepenbrock, and K. A. Tanaka
Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study
Br. J. Anaesth.,
June 1, 2009;
102(6):
785 - 792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Bolliger, F. Szlam, R. J. Molinaro, N. Rahe-Meyer, J. H. Levy, and K. A. Tanaka
Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model
Br. J. Anaesth.,
June 1, 2009;
102(6):
793 - 799.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|